Latest Breaking News On - Professor matt rettig - Page 1 : comparemela.com

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Boca ratonUnited statesDavid mossMatt rettigInmune bioJason nelsonDrug administrationDavid geffen school of medicineCompany current reports on formProstate cancer programUniversity of californiaInmune bio incCompany annual report on formExchange commissionJonsson comprehensive cancer centerCompany quarterly reports on form

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune in Patients with Metastatic Castration-Resistant Prostate Cancer

02.01.2024 - Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, dosed . Seite 1

Boca ratonUnited statesMatt rettigUniversity of californiaJonsson comprehensive cancer centerDavid geffen school of medicineProstate cancer programInmune bio incProfessor matt rettigMedical directorGeffen schoolJonsson comprehensive cancerProfessor rettigInmune bio chartNmune bio kursInmune bio aktie